

## **Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

### **Listing of Claims:**

Claims 1-14. (Canceled)

Claim 15. (Withdrawn and Currently Amended) A method for the treatment of hypertension, congestive heart failure, angina, myocardial infarction, ~~atherosclerosis~~atherosclerosis, diabetic nephropathy, diabetic cardiac myopathy, renal insufficiency, peripheral vascular disease, left ventricular hypertrophy, cognitive dysfunction, stroke, headache and chronic heart failure which method comprises administering a therapeutically effective amount of a solid oral dosage form according to Claim 1 to a patient in need thereof.

Claim 16. (Withdrawn and Currently Amended) A method for the treatment of hypertension, congestive heart failure, angina, myocardial infarction, ~~atherosclerosis~~atherosclerosis, diabetic nephropathy, diabetic cardiac myopathy, renal insufficiency, peripheral vascular disease, left ventricular hypertrophy, cognitive dysfunction, stroke, headache and chronic heart failure which method comprises administering a therapeutically effective amount of a solid oral dosage form according to Claim 12 to a patient in need thereof.

Claim 17. (Withdrawn and Currently Amended) Use of a solid oral dosage form according to Claim 1 for the manufacture of a medicament for the treatment of hypertension, congestive heart failure, angina, myocardial infarction, ~~atherosclerosis~~atherosclerosis, diabetic nephropathy, diabetic cardiac myopathy, renal insufficiency, peripheral vascular disease, left ventricular hypertrophy, cognitive dysfunction, stroke, headache and chronic heart failure.

Claim 18. (Withdrawn and Currently Amended) Use of a solid oral dosage form according to Claim 12 for the manufacture of a medicament for the treatment of hypertension, congestive heart failure, angina, myocardial infarction, ~~atherosclerosis~~atherosclerosis, diabetic nephropathy, diabetic cardiac myopathy, renal insufficiency, peripheral vascular disease, left ventricular hypertrophy, cognitive dysfunction, stroke, headache and chronic heart failure.

Claim 19. (Withdrawn) A process for the manufacture of a solid oral dosage form according to Claim 12 comprising:

- 1) mixing the active ingredient and additives and granulating said components with a granulation liquid;
- 2) drying a resulting granulate;
- 3) mixing the dried granulate with outer phase excipients;
- 4) compressing a resulting mixture to form a solid oral dosage as a core tablet;
- and
- 5) optionally coating a resulting core tablet to give a film-coated tablet.

Claim 20. (Withdrawn) A process according to Claim 19. wherein the additives in step (1) are selected from a filler, a disintegrant and a binder; and the outer phase excipients in step (3) are selected from a filler, a disintegrant, a lubricant and a glidant.

Claim 21. (Previously Presented) A solid oral dosage form comprising a therapeutically effective amount of aliskiren, or a pharmaceutically acceptable salt thereof, in an amount of more than 46% by weight based on the total weight of the oral dosage form, wherein the oral dosage form is in the form of a tablet and is not obtainable by wet granulation with excipients using water and/or an aqueous binder solution.

Claim 22. (Previously Presented) The solid oral dosage form according to Claim 21, wherein the tablet is a film-coated tablet.

Claim 23. (Withdrawn) The solid oral dosage form according to Claim 21, wherein the tablet is chosen from a tablet in the form of multiparticulates, multiparticulate pellets, multiparticulate minitabets, wax matrix systems, polymer matrix tablets, polymer coated tablets, oral osmotic systems, coated tablets, matrix tablets, press-coated tablets, and multilayer tablets.

Claim 24. (Previously Presented) The solid oral dosage form according to Claim 21, obtainable by organic wet granulation.

Claim 25. (Previously Presented) The solid oral dosage form according to Claim 24, obtainable by wet granulation using a mixture of organic solvents or an organic binder solution.

Claim 26. (Previously Presented) A solid oral dosage form according to Claim 21, wherein the active ingredient is present in an amount of more than 48% by weight.

Claim 27. (Previously Presented) A solid oral dosage form according to Claim 21, wherein the active ingredient is present in an amount ranging from 46 to 60% by weight.

Claim 28. (Previously Presented) A solid oral dosage form according to Claim 27, wherein the active ingredient consists entirely of aliskiren, or a pharmaceutically acceptable salt thereof, and is present in an amount ranging from about 75 to about 600 mg of the free base per unit dosage form.

Claim 29. (Previously Presented) A solid oral dosage form according to Claim 28, wherein the active ingredient consists entirely of aliskiren, or a pharmaceutically

acceptable salt thereof, and is present in an amount ranging from about 75 to about 300 mg of the free base per unit dosage form.

Claim 30. (Previously Presented) A solid oral dosage form according to Claim 29, wherein aliskiren is in the form of a hemi-fumarate thereof, and is present in an amount of about 83 mg per unit dosage form.

Claim 31. (Previously Presented) A solid oral dosage form according to Claim 30, wherein aliskiren is in the form of a hemi-fumarate thereof, and is present in an amount of about 166 mg per unit dosage form.

Claim 32. (Previously Presented) A solid oral dosage form according to Claim 31, wherein aliskiren is in the form of a hemi-fumarate thereof, and is present in an amount of about 332 mg per unit dosage form.

Claim 33. (Previously Presented) A solid oral dosage form according to any of Claims 29-31, wherein the dosage form further comprises a filler.

Claim 34. (Previously Presented) A solid oral dosage form according to Claim 33, wherein the filler is microcrystalline cellulose.

Claim 35. (Previously Presented) A solid oral dosage form according to Claim 33, wherein the dosage form further comprises a disintegrant.

Claim 36. (Previously Presented) A solid oral dosage form according to Claim 35, wherein the dosage form further comprises a lubricant.

Claim 37. (Previously Presented) A solid oral dosage form according to Claim 36, wherein the dosage form further comprises a glidant.

Claim 38. (Previously Presented) A solid oral dosage form according to Claim 37, wherein the dosage form further comprises a binder.

Claim 39. (Previously Presented) A solid oral dosage form according to Claim 21 for use in the manufacture of a medicament for the treatment of hypertension, congestive heart failure, angina, myocardial infarction, atherosclerosis, diabetic nephropathy, diabetic cardiac myopathy, renal insufficiency, peripheral vascular disease, left ventricular hypertrophy, cognitive dysfunction, stroke, headache and chronic heart failure.